Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

26.01 -0.12

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

25.63

Massimo

26.16

Metriche Chiave

By Trading Economics

Entrata

191K

-51M

Vendite

6.7M

106M

EPS

-0.46

Margine di Profitto

-47.808

Dipendenti

1,784

EBITDA

-2.1M

-46M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+39.62% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

826M

2.9B

Apertura precedente

26.13

Chiusura precedente

26.01

Notizie sul Sentiment di mercato

By Acuity

50%

50%

171 / 340 Classifica in Healthcare

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 ago 2026, 23:51 UTC

News

Enova International's subsidiary issued $300.89 million in notes, contributing to positive sentiment. The stock is higher in after-market trading, despite recent volatility.

21 ago 2026, 23:46 UTC

News

Home Depot expands roles for three executives, awarding $500,000 in stock grants. Shares were roughly flat during after-market hours following the announcement.

21 ago 2026, 23:41 UTC

News
ETF Constituents

SPDR Dow Jones Industrial Average ETF Trust rises in after-market trading, bolstered by gains from UnitedHealth Group and Merck, despite broader market declines.

21 ago 2026, 23:36 UTC

News

Coty Inc reported a fourth-quarter revenue beat but issued weak guidance, resulting in shares trading lower in after-market hours.

21 ago 2026, 23:31 UTC

Correlated Moves
News

Ethereum's price reached $2,371 today, driven by anticipation of Pepeto's Binance listing and Bitcoin's rally past $79,000, boosting market sentiment.

21 ago 2026, 23:26 UTC

Correlated Moves
News

Citigroup Inc shares are lower during after-market hours, reflecting a slight decline amid broader market trends influenced by geopolitical tensions and bargain hunting.

21 ago 2026, 23:21 UTC

Correlated Moves
News
Social Media

Coinbase Global Inc is rising in after-market trading, supported by Bitcoin's significant gain. The company also launched a feature for immediate token access.

21 ago 2026, 23:06 UTC

News

Verizon Communications is deploying resources in response to a potential tropical storm in Hawaii, contributing to lower shares after Friday's close.

21 ago 2026, 23:06 UTC

Correlated Moves
News

KKR & Co Inc reported a net asset value of $8.49 billion as of July 31, contributing to positive sentiment in after-market trading.

21 ago 2026, 23:01 UTC

Social Media
News

Applied Optoelectronics Inc. plans to sell up to $600 million in shares, contributing to a decline in after-market trading amid dilution concerns.

21 ago 2026, 23:01 UTC

News

Hess Midstream LP shares are advancing in after-market trading following a dividend increase and improved free cash flow, despite lower EBITDA and net income.

21 ago 2026, 23:01 UTC

News

Texas Pacific Land Corp shares are higher in after-hours trading, with a market capitalization of $26.49 billion reflecting strong long-term performance.

21 ago 2026, 23:01 UTC

News
Social Media

Sigma Lithium Corp resumes full operations under a new agreement in Brazil, targeting 240,000 tonnes of lithium oxide concentrate. Shares are advancing in after-market trading.

21 ago 2026, 23:01 UTC

News

Spectrum Brands Holdings Inc shares are higher in after-market trading. The company expects low-single-digit revenue growth for fiscal year 2026 amid ongoing cost pressures.

21 ago 2026, 22:01 UTC

News

Cytek Biosciences shares are lower in after-market hours following a jury's $56 million damages award to Beckman Coulter for patent infringement.

21 ago 2026, 20:07 UTC

News
Social Media

Microsoft shares are higher, supported by bullish options activity and a reaffirmed AAA rating from Moody's. The company is part of a $615 billion AI investment group.

21 ago 2026, 20:07 UTC

Social Media
News

Palantir Technologies shares are higher today amid increased options trading and positive sentiment, with Deutsche Bank reiterating a $200 price target.

21 ago 2026, 20:07 UTC

News

Aflac shares are lower today as Japan Post sold 12,700 shares, contributing to negative sentiment amid broader market declines since Thursday's close.

21 ago 2026, 20:07 UTC

News

United Parcel Service shares are trading lower as Zacks cuts Q3 EPS estimate to $1.60. Susquehanna raises target price to $120, maintaining a neutral rating.

21 ago 2026, 20:07 UTC

News

Barclays maintains an Overweight rating on Hims & Hers Health, lowering its price target to $35. Shares are trading higher amid positive market sentiment.

21 ago 2026, 20:07 UTC

News
Correlated Moves

The USD/SEK is trading lower today, continuing a decline since Thursday's close. Earlier in the session, the dollar rebounded from a session low.

21 ago 2026, 20:06 UTC

News

Nu Holdings is higher today, buoyed by a rise in Bitcoin prices following the U.S. Treasury's announcement to double long-dated bond buybacks.

21 ago 2026, 20:06 UTC

News
Correlated Moves

Gold prices are rising, reaching a near three-month high, driven by U.S. Treasury bond buybacks and President Trump's shift in Iran policy.

21 ago 2026, 20:06 UTC

Correlated Moves
News

First Western Financial promotes Brian Weldon to Regional President and Bryce Parietti and Rob Miles to Market Presidents, with shares trading higher today.

21 ago 2026, 20:06 UTC

News

Liquidity Services shares are higher after announcing CEO Bill Angrick's presentation at the Midwest IDEAS Investor Conference on August 26, 2026, in Chicago.

21 ago 2026, 20:06 UTC

News

Palo Alto Networks shares are higher following multiple analyst price target increases, including Cantor Fitzgerald's raise to $425 from $340.

21 ago 2026, 20:06 UTC

News

Citizens Inc shares are lower today, continuing a decline since Thursday amid broader market downturns. The stock remains below its 20-day moving average.

21 ago 2026, 20:06 UTC

News
Social Media

Stoke Therapeutics shares rise following analyst reinstatement with Overweight rating and $40 price target, amid positive sentiment for zorevunersen’s phase III EMPEROR trial.

21 ago 2026, 20:06 UTC

News

T Rowe Price shares are lower as the company pursues its acquisition of F/M Investments, which manages over $10 billion in ETF assets.

21 ago 2026, 20:06 UTC

News

Salesforce Inc is higher as investor interest grows ahead of its August 26 earnings report, with a revenue target of $11.3 billion for Q2.

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

39.62% in crescita

Previsioni per 12 mesi

Media 36.33 USD  39.62%

Alto 45 USD

Basso 27 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

171 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat